彩娱乐官网（中国）有限责任公司 新式降糖药物“恩威并济”，助力糖尿病处罚“天平地安”

*仅供医学专科东说念主士阅读参考

GLP‑1RA“兼顾统筹”多重危机成分，握续鼓励“糖心肾”三重获益。

近40年来，2型糖尿病（T2DM）患病率逐年高涨，对东说念主类健康组成严重阻扰，为社会经济发展及医疗卫生体系拓荒带来要紧挑战。跟着T2DM病程的阐述，短期和永久血糖浪漫欠安加多了微血管和大血管并发症风险[1]。而在宽绰的并发症中，动脉粥样硬化性疾病（ASCVD）是最常见的一类，其致死率已占糖尿病患者升天率的50%操纵[2‑3]。

跟着越来越多循证医学笔据的出现，T2DM颐养理念发生振荡，从开端的强化降糖到兼顾个体化各异，再到强调代谢多成分玄虚处罚及强调温舒适血劳动件。理思的T2DM颐养药物需要知足以下几点：降糖疗效详情，低血糖风险小，可改善患者体质地指数（BMI），并可带来心肾获益。

出谋献计，直击中枢，全面优化血糖处罚

降糖颐养是T2DM处罚的中枢，以达到理思的糖化血红卵白（HbA1c）水平为主义[4]。达到主义血糖水平，尤其在T2DM会诊后的早期，将血糖浪漫在主义规模内，可裁减微血管并发症的发生率和阐述，永久（10年以上）可裁减心血管结局[5]。

Pura 80 Ultra的摄像头系统包括超聚光主摄、超聚光微距长焦和超广角摄像头，三者协同工作，确保每一张照片都忠于原色，呈现出最佳拍摄效果。

这孩子平时工作能力肯定很强的，否则领导也不会把这么重要的讲解任务交给她，而且人家只是素颜而已，头发也是扎起来的，只是风大吹的有点散。

连年来，胰高糖素样肽‑1受体欣喜剂（GLP‑1RA）因其优异的降糖后果深受各大指南的爱好，颐养地位渐渐攀升。胰高糖素样肽‑1（GLP‑1）可通过葡萄糖浓度依赖的样子促进胰岛素分泌，扼制胰高血糖素分泌，裁减血糖。此外，其还具有减慢胃排空、扼制食欲，以及潜在的扼制β细胞凋一火等多种生理作用[6]。

商量阐发，与日制剂比拟，GLP‑1RA周制剂具有更巩固的血药浓度，患者可得回永久颐养的顺从性[7,8]。四肢新式GLP‑1RA周制剂，司好意思格鲁肽与自然东说念主GLP‑1氨基酸序列具有高达94%的同源性，半衰期长达7天，皮下给药时血药浓度波动更小。SUSTAIN系列商量阐发[9-16]，司好意思格鲁肽单药、集会一种或两种口服药物以及集会基础胰岛素均可显赫裁减HbA1c水平。以中国东说念主群为主的多中心临床锻练SUSTAIN China商量，在二甲双胍颐养后果欠安的早期T2DM东说念主群中阐发了司好意思格鲁肽的疗效，中国T2DM东说念主群HbA1c裁减达1.8%，HbA1c达标率达86.1%[10,17]。

聚焦风险，玄虚防控，全面改善心肾结局

T2DM患者常归拢肥美、高血压、血脂异等，迪士尼彩乐园3手机版导致糖尿病患者ASCVD患病率显赫升高[18]。此外，部分传统降糖药物概况加多体重，进一步加多了胰岛素抗争，从而不利于血糖和血压的浪漫。因此关于T2DM患者，在控糖的同期亦应温煦减重、浪漫血压和血脂，改善胰岛素抗争。

在一项绽放、对照、平行锻练中，对归拢多重ASCVD危机成分的T2DM患者弃取玄虚强化颐养次第，包括降糖、降压、调脂及抗血小板等，历经13.3年的随访，主要尽头事件弥散风险下跌20%[19]。该商量阐发，在T2DM早期进行多重危机成分阻挠可带来尽头事件获益。

好意思国糖尿病协会（ADA）及中华医学会糖尿病学分会（CDS）新近发布的T2DM处罚指南均强调，为减少主要不良心血劳动件（MACE）风险，提出归拢ASCVD或心血管风险高危的患者，无论其HbA1c是否达标，惟有莫得禁忌证，齐应加器具有ASCVD获益笔据的GLP‑1RA颐养[4,20]。包括群众56004例患者的7项大型临床商量汇注分析露出，GLP‑1RA类药物可显赫裁减3P‑MACE（心血管升天或非致死性心肌梗死或非致死性卒中复合事件）12%，裁减心血管升天风险12%，减少致死性和非致死性卒中16%，减少致死性或非致死性心肌梗死9%，裁减全因升天风险12%，减少因心力穷乏入院9%，减少肾脏复合尽头（新发广博卵白尿、下跌30%、阐述至最后期肾病或肾脏疾病导致升天）17%，且未不雅察到严重低血糖、胰腺癌及胰腺热风险加多[21]。

在我国，司好意思格鲁肽是第一个上市的具有心血管获益笔据的GLP‑1RA周制剂，非论基线心血管风险怎样，其齐不错显赫裁减T2DM患者MACE风险和非致死性卒中风险，且安全性较好[22,23]。此外，司好意思格鲁肽概况裁减新发肾病及肾病阐述率，显赫减少肾脏风险达36%，改善肾脏结局[24]，况且概况裁减放松压，裁减总胆固醇、甘油三酯和胆固醇水平[25]，改善T2DM患者多要点血管代谢危机成分，从而匡助糖尿病患者开脱多重逆境，改善临床结局和生涯质地。

小结

说七说八，国表里颐养指南及循证笔据夯实了GLP‑1RA类药物在归拢心血管疾病或心血管高风险T2DM患者中的蹙迫颐养地位。GLP‑1RA因其多重作用机制，在T2DM处罚经由中起到了“追根问底，直面中枢”的作用。司好意思格鲁肽在灵验改善胰岛β细胞功能、强效降糖的同期，兼具降压、调脂等上风，为患者带来了心血管、肾脏代谢的玄虚获益，加多了颐养顺从性，优化了T2DM玄虚处罚后果。

大家简介

赖红梅 西席

主任医生，医学博士，硕士商量生导师

新疆自治区东说念主民病院心内科四病区主任

卫生部冠心病介入培训基地导师

新疆医学会第四届心血管病专科委员会常务委员

中国医生协会胸痛专科委员会胸痛影像与介入学组委员

新疆结构性腹黑瓣膜病介入质控委员会委员

新疆抗癌协会整合肿瘤腹黑病学专委会委员

主要从事冠心病介入以及心肌损害退缩与保衬规模商量

参考文件：

[1]Philis‑Tsimikas A, Astamirova K, Gupta Y, et al. Similar glycaemic control with less nocturnal hypoglycaemia in a 38‑week trial comparing the IDegAsp co‑formulation with insulin glargine U100 and insulin aspart in basal insulin‑treated subjects with type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 2019, 147: 157‑165.

[2]Authors/Task Force Members, Rydén L, Grant PJ, et al. ESC Guidelines on diabetes, pre‑diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre‑diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)[J]. Eur Heart J, 2013, 34(39): 3035‑3087.

[3]Rodriguez F, Blum MR, Falasinnu T, et al. Diabetes‑attributable mortality in the United States from 2003 to 2016 using a multiple‑cause‑of‑death approach[J]. Diabetes Res Clin Pract, 2019, 148:169‑178.

[4]中华医学会糖尿病学分会. 中国2型糖尿病防治指南 (2020年版) [J]. 中华糖尿病杂志,2021,13(4):315‐409.

[5]Senior PA, Houlden RL, Kim J, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update‑the user′s guide[J]. Can J Diabetes, 2020, 44(7):592‑596.

[6]Meier JJ. GLP‑1 receptor agonists for individualized treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2012, 8(12): 728‑742.

[7]Federici MO, McQuillan J, Biricolti G, et al. Utilization patterns of glucagon‑like peptide‑1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study[J]. Diabetes Ther, 2018, 9(2):789‑801.

[8]Mody R, Huang Q, Yu M, et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‑month follow‑up in a real‑world setting in the United States[J]. Diabetes Obes Metab, 2019, 21(4):920‑929.

[9]Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once‑weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double‑blind, randomised, placebo‑controlled, parallel‑group, multinational, multicentre phase 3a trial[J]. Lancet Diabetes Endocrinol, 2017, 5(4):251‑260.

[10]Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once‑weekly semaglutide versus once‑daily sitagliptin as an add‑on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56‑week, double‑blind, phase 3a, randomised trial[J]. Lancet Diabetes Endocrinol, 2017, 5(5):341‑354.

[11]Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once‑weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56‑week, open‑label, randomized clinical trial[J]. Diabetes Care,2018, 41(2):258‑266.

[12]Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once‑weekly semaglutide versus once‑daily insulin glargine as add‑on to metformin (with or without sulfonylureas) in insulin‑naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open‑label, parallel‑group, multicentre, multinational, phase 3a trial [J]. Lancet Diabetes Endocrinol, 2017, 5(5):355‑366.

[13]Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial[J]. J Clin Endocrinol Metab, 2018, 103(6):2291‑2301.

[14]Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open‑label, phase 3b trial[J]. Lancet Diabetes Endocrinol, 2018, 6(4): 275‑286.

[15]Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once‑weekly semaglutide versus daily canagliflozin as add‑on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double‑blind, phase 3b, randomized controlled trial[J]. Lancet Diabetes Endocrinol, 2019,7(11):834‑844.

[16]Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add‑on to SGLT‑2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo‑controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(5): 356‑367.

[17]Ji L, Dong X, Li Y, et al. Efficacy and safety of once‑weekly semaglutide versus once‑daily sitagliptin as add‑on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30‑week, double‑blind, phase 3a, randomized trial[J]. Diabetes Obes Metab, 2021, 23(2):404‑414.

[18]潘敬芳, 刘云涛, 简磊. 利拉鲁肽对2型糖尿病归拢患者颈动脉内膜中层厚度的影响[J]. 中国老年学杂志, 2017, 37(15): 3761‑3762.

[19]Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study[J]. Lancet, 1999, 353(9153): 617‑622.

[20]American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes‑2022[J]. Diabetes Care, 2022, 45(Suppl 1):S17‑S38.

[21]Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta‑analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776‑785.

[22]Verma S, Fainberg U, Husain M, et al. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: an exploratory analysis of cardiovascular outcomes with semaglutide[J]. Diabetes Obes Metab, 2021, 23(7):1677‑1680.

[23]Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk[J]. Diabetes Obes Metab, 2020, 22(3): 442‑451.

[24]Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes [J]. N Engl J Med, 2016, 375(19): 1834‑1844.

[25]Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add‑on to SGLT‑2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo‑controlled trial[J]. Lancet Diabetes Endocrinol, 2019 May; 7(5):356‑367.

“此文仅用于向医疗卫生专科东说念主士提供科学信息，不代表平台态度”